A Phase 2a, Multi-Center, Randomized, Parallel Group, Double Blind and Placebo-controlled Clinical Trial to Assess Safety and Tolerability as well as Explorative Efficacy of the Orthosteric Selective Muscarinic M1 Agonist NSC001 in Mild to Moderate Alzheimer’s Disease - NSC24001
100 项与 Nsc Therapeutics GmbH 相关的临床结果
0 项与 Nsc Therapeutics GmbH 相关的专利(医药)
100 项与 Nsc Therapeutics GmbH 相关的药物交易
100 项与 Nsc Therapeutics GmbH 相关的转化医学